Medibact GuidesShop at Medibact

Stacking Module

BPC-157 Stacking Module

BPC-157 is the most-combined peptide in the repair category, and it anchors all three of the well-known pre-mixed blends. That popularity means most of what circulates about stacking it is inherited from vendor marketing rather than research, so this module separates what the mechanism-level rationale actually is from what has been demonstrated — which, for every combination below, is less than the marketing implies.

BPC-157 Guide at MedibactBPC-157 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking BPC-157

  • BPC-157 is the base, not the addition. In every named blend it is the component the others are added to, so the practical question is usually what a second compound adds rather than whether BPC-157 belongs.
  • It is dosed in micrograms while several common partners (TB-500, GHK-Cu) are dosed in milligrams. Syringe-unit figures are therefore never transferable between them even at identical concentrations — a recurring source of error when people carry a unit count across compounds.
  • It is prohibited by WADA. For anyone subject to anti-doping testing, that fact governs regardless of what a stack rationale says.
  • No controlled trial has studied BPC-157 combined with anything. Every rationale below is inference from separate single-compound literatures, and interactions are unstudied rather than known to be absent.

Combinations in detail

Wolverine

BPC-157 + TB-500
Why it is proposed
The most-discussed pairing in tissue-repair contexts. The mechanism-level argument is that the two act on different stages of the same process: BPC-157 is studied for angiogenesis and tendon-to-bone healing, while TB-500 is studied for actin regulation and cell migration — the process by which repair cells reach a site at all. Complementary rather than duplicative, in principle.
What is reported in practice
Reported practice runs both concurrently, with BPC-157 more frequently than TB-500 because of the shorter reported dosing interval, and TB-500 on a milligram scale versus BPC-157's micrograms. Community protocols commonly describe a defined block of weeks rather than continuous use.
Cautions specific to this combination
The scale difference is the practical hazard: a unit count that is correct for one is badly wrong for the other. TB-500 is a fragment of a larger protein and is frequently mislabelled by vendors, so a mass-spec COA is the only way to know which molecule is actually present.

GLOW

BPC-157 + TB-500 + GHK-Cu
Why it is proposed
Wolverine with GHK-Cu added, shifting the stated focus toward collagen synthesis and skin/tissue remodeling. GHK-Cu contributes a genuinely different mechanism — copper delivery and matrix-remodeling gene expression rather than repair signaling.
What is reported in practice
Usually encountered as a pre-mixed blend vial rather than three separate vials. Reported practice mirrors Wolverine with the blend administered as a single draw, which fixes the ratio of all three components together.
Cautions specific to this combination
GHK-Cu's strongest human evidence is for topical cosmetic formulations, not injection — the topical literature's strength does not transfer to an injected blend. Copper is also cumulative, which is the usual rationale for defined breaks rather than continuous use.

KLOW

BPC-157 + TB-500 + GHK-Cu + KPV
Why it is proposed
GLOW plus KPV, adding an anti-inflammatory element. KPV is a fragment of alpha-MSH studied for inflammatory signaling, particularly in gut and skin contexts — which is the stated reason KLOW is often discussed for gut-focused research alongside BPC-157's own gastrointestinal literature.
What is reported in practice
Almost always a pre-mixed 80 mg vial. Because four components sit at four different concentrations in one solution, a single draw delivers a fixed ratio of all four and no component can be adjusted independently.
Cautions specific to this combination
This is the combination with the widest gap between marketing confidence and evidence: four compounds, none FDA-approved, zero combination data. Sources also disagree on what KLOW even contains — a minority define it as KPV plus BPC-157 only.

Gut-focused pairing

BPC-157 + KPV
Why it is proposed
Discussed where gastrointestinal inflammation is the focus rather than musculoskeletal repair. The argument is that BPC-157's gastrointestinal literature and KPV's inflammatory-signaling literature address different sides of the same picture — barrier repair and immune signaling.
What is reported in practice
Reported both as separate vials and as the KLOW blend's two 'K' and 'B' components. Oral and localized administration are discussed more for this pairing than for the musculoskeletal stacks.
Cautions specific to this combination
Human data for both compounds are limited, and for gut-focused use specifically the evidence is preclinical. Any gastrointestinal symptom serious enough to prompt this kind of interest warrants a clinician rather than a peptide protocol.

What to avoid, and why

  • Adding a second repair-signaling compound with the same proposed mechanism generally reads as redundant rather than additive in the reported discussion — the rationale for all the named blends is that each component does something different.
  • Carrying a syringe-unit figure from TB-500 or GHK-Cu across to BPC-157. They are dosed on different scales; recompute from concentration every time.
  • Treating a pre-mixed blend as interchangeable with separate vials when following a protocol written for one or the other — the per-component amounts are not the same.

If you are using a pre-mixed blend

Because this compound is sold inside pre-mixed blend vials as well as on its own, one more arithmetic point matters: a blend label's milligram figure is the combined mass of all its components, and vendors do not standardise the per-component split. You cannot derive any single component's concentration from the blend total, and a volume figure that applied to one vendor's vial does not transfer to another's. Separate vials remove that ambiguity entirely, at the cost of more injections.

Related reading

Wolverine — BPC-157 + TB-500GLOW — BPC-157 + TB-500 + GHK-CuKLOW — BPC-157 + TB-500 + GHK-Cu + KPVThe Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.